



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Marina I. Garin

✉ marina.garin@ciemat.es

Mercedes Lopez-Santalla

✉ mercedes.lopezsantalla@ciemat.es

RECEIVED 08 February 2024

ACCEPTED 26 April 2024

PUBLISHED 08 May 2024

## CITATION

Lopez-Santalla M, Conde C,  
Rodriguez-Trillo A and Garin MI (2024)  
Corrigendum: Assessment of mesenchymal  
stem/stromal cell-based therapy in K/BxN  
serum transfer-induced arthritis.  
*Front. Immunol.* 15:1384171.  
doi: 10.3389/fimmu.2024.1384171

## COPYRIGHT

© 2024 Lopez-Santalla, Conde,  
Rodriguez-Trillo and Garin. This is an open-  
access article distributed under the terms of  
the [Creative Commons Attribution License  
\(CC BY\)](#). The use, distribution or reproduction  
in other forums is permitted, provided the  
original author(s) and the copyright owner(s)  
are credited and that the original publication  
in this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis

Mercedes Lopez-Santalla<sup>1,2,3\*</sup>, Carmen Conde<sup>4</sup>,  
Angela Rodriguez-Trillo<sup>4</sup> and Marina I. Garin<sup>1,2,3\*</sup>

<sup>1</sup>Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain, <sup>2</sup>Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Madrid, Spain, <sup>3</sup>Advanced Therapy Unit, Health Research Institute- Fundación Jiménez Díaz, University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain, <sup>4</sup>Laboratorio de Reumatología Experimental y Observacional, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain

## KEYWORDS

mesenchymal stem/stromal cell-based therapy, K/BxN serum transfer-induced arthritis, joint inflammation, cell therapy, immunomodulation

## A Corrigendum on

### Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis

By Lopez-Santalla M, Conde C, Rodriguez-Trillo A and Garin MI (2022). *Front. Immunol.* 13:943293. doi: 10.3389/fimmu.2022.943293

In the published article, there was a mistake in the Funding statement. The Funding statement for the “Instituto de Salud Carlos III (ISCIII)” was displayed as “Instituto de Salud Carlos III (ISCIII)” (PIE15/00048, PI17/01161, PI21/01441, PI20/01266, RICORS; RD21/0017/00’.

The correct statement is as follows:

“This work was supported by grants from “Instituto de Salud Carlos III (ISCIII)”, co-funded by the European Union (PIE15/00048, PI17/01161, PI21/01441, PI20/01266, RICORS; RD21/0017/00; funded by European Union-NextGenerationEU. Plan de Recuperación Transformación y siliencia) and Comunidad de Madrid (AvanCell, B2017/BMD-3692). CIBERER is an initiative of the “Instituto de Salud Carlos III” and the European Regional Development Fund (ERDF)’.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.